Omeros Balance Sheet Health
Financial Health criteria checks 2/6
Omeros has a total shareholder equity of $-25.0M and total debt of $338.3M, which brings its debt-to-equity ratio to -1354%. Its total assets and total liabilities are $378.3M and $403.3M respectively.
Key information
-1,354.0%
Debt to equity ratio
US$338.28m
Debt
| Interest coverage ratio | n/a |
| Cash | US$171.85m |
| Equity | -US$24.98m |
| Total liabilities | US$403.25m |
| Total assets | US$378.27m |
Recent financial health updates
Is Omeros (NASDAQ:OMER) A Risky Investment?
Jul 26
Omeros (NASDAQ:OMER) Is Making Moderate Use Of Debt
Mar 17Recent updates
Omeros: Still Worth A Look Despite Narsoplimab Woes
Feb 14Is Omeros (NASDAQ:OMER) A Risky Investment?
Jul 26Omeros (NASDAQ:OMER) Is Making Moderate Use Of Debt
Mar 17Omeros: Taking It To The Max
Oct 05Omeros falls 11% after reporting clinical data for COVID-19 therapy
Sep 15Omeros: Managing An Investment After A Winning Trade
Aug 16Omeros granted FDA’s Orphan Drug designation for PNH candidate
Jul 28Omeros: Follow The Bouncing Ball
Jul 04Omeros: On Death's Door
Jun 02Omeros: The Weight Of The Wait, A Conundrum
May 03Omeros: Despite Its Promise, The CRL Is A Huge Obstacle
Feb 21Omeros: A New Year Beckons
Dec 06Some Analysts Just Cut Their Omeros Corporation (NASDAQ:OMER) Estimates
Dec 04Omeros: What's Left
Oct 15Omeros: The Prize Is Nigh (Again)
Sep 14Omeros: PDUFA Delay Presents An Opportunity
Jul 03Omeros posts preliminary results from early-stage OMS906 trial
Jun 09Should Shareholders Reconsider Omeros Corporation's (NASDAQ:OMER) CEO Compensation Package?
Jun 05Omeros posts preliminary results from COVID-19 patients treated with narsoplimab
May 28CDC and CMS OKs Omeros' ICD-10 codes for HSCT-TMA diagnosis and narsoplimab
May 04What Kind Of Shareholders Own Omeros Corporation (NASDAQ:OMER)?
Mar 03Update: Omeros (NASDAQ:OMER) Stock Gained 73% In The Last Five Years
Jan 27Omeros: A Ripening Fruit Ready To Pick
Dec 09Omeros: Ending 2020 On Some High Notes
Dec 05Rainbows and Unicorns: Omeros Corporation (NASDAQ:OMER) Analysts Just Became A Lot More Optimistic
Dec 05
Financial Position Analysis
Short Term Liabilities: OMER has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: OMER has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: OMER has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: OMER's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable OMER has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: OMER is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 20.3% per year.